Human umbilical cord blood stem cells therapy (Nanjing Medical University)

人体脐带血干细胞疗法（南京医科大学）

Report date: 2022/12/27 09:23:09

Base Information

Drug NameHuman umbilical cord blood stem cells therapy (Nanjing Medical University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derivedCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesThe First Affiliated Hospital With Nanjing Medical University
China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital With Nanjing Medical University
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A